SCHEMBL143778

SCHEMBL143778

C[C@H](O)C(=O)Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 18/20 0.78
KDR P35968 10/20 0.78
NTRK1 P04629 3/20 0.78
TEK Q02763 2/20 0.78
NTRK3 Q16288 1/20 0.78
NTRK2 Q16620 1/20 0.78
RET P07949 3/20 0.53
FLT3 P36888 3/20 0.53
RIPK2 O43353 2/20 0.53
ABL1 P00519 2/20 0.53
LCK P06239 2/20 0.53
LYN P07948 2/20 0.53
HCK P08631 2/20 0.53
BCR P11274 2/20 0.53
EPHA2 P29317 2/20 0.53
ABL2 P42684 2/20 0.53
FRK P42685 2/20 0.53
MST1R Q04912 2/20 0.53
DDR1 Q08345 2/20 0.53
MAP2K5 Q13163 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143639 1.00 MET (0.78) METKDRNTRK1TEKNTRK3
SCHEMBL143640 1.00 MET (0.78) METKDRNTRK1TEKNTRK3
SCHEMBL138412 0.95 MET (0.78) METKDRNTRK1TEKNTRK3
SCHEMBL15512245 0.93 MET (0.75) METKDRNTRK1TEKNTRK3
SCHEMBL142782 0.93 MET (0.75) METKDRNTRK1TEKNTRK3
SCHEMBL142781 0.93 MET (0.75) METKDRNTRK1TEKNTRK3
SCHEMBL139087 0.91 MET (0.72) METKDRNTRK1TEKNTRK3
SCHEMBL139086 0.91 MET (0.72) METKDRNTRK1TEKNTRK3
SCHEMBL138396 0.90 MET (0.82) METKDRNTRK1TEKNTRK3
SCHEMBL15512908 0.90 MET (0.71) METKDRNTRK1TEKNTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150218130-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2015-08-06 US disclosed
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-07-10 US disclosed
EP-2563362-B1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS LLC (US) 2014-03-12 EP disclosed
US-8637672-B2 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-01-28 US disclosed
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-12-20 US disclosed
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHAMACEUTICALS, LLC (US) 2012-10-04 US disclosed
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885KDR 3640/4885NTRK1 3749/4885
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885KDR 3640/4885NTRK1 3749/4885
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885KDR 3640/4885NTRK1 3749/4885
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885KDR 3640/4885NTRK1 3749/4885
US-20150218130-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MET 2169/4885KDR 3640/4885NTRK1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.